---
input_text: Bone marrow transplant using fludarabine-based reduced intensity conditioning
  regimen with in vivo T cell depletion in patients with Fanconi anemia. FA is the
  most common cause of inherited BMF syndromes. The only cure for BMF in FA remains
  HSCT. Due to DNA instability in FA, RIC has been used to decrease immediate and
  late complications of HSCT. Most FA conditioning regimens in mismatched and unrelated
  donor transplants rely on TBI, which increases the risk of secondary malignancies.
  Most of the non-TBI conditioning regimens use an ex vivo T-cell depletion approach,
  but this is not feasible at all pediatric stem cell transplant programs. To evaluate
  the success of HSCT in patients with FA using non-TBI conditioning regimens with
  in vivo T-cell depletion approach. HSCT using non-TBI based conditioning was performed
  on two siblings with FA. The first sibling underwent matched unrelated donor transplant
  with a BM graft using fludarabine, alemtuzumab, busulfan, and cyclophosphamide conditioning
  and cyclosporine and mycophenolate as GVHD prophylaxis. The second sibling underwent
  MSD transplant with UCB and BM grafts using similar approach, but without busulfan
  and mycophenolate. Both siblings had engraftment without signs of acute or chronic
  GVHD. Acute post-transplant complications included brief viral reactivations. At
  last follow-up, both siblings continued to have full immune reconstitution with
  stable chimerism. Conditioning regimens without radiation and inclusion of alemtuzumab
  can lead to successful engraftment without development of GVHD and reduce risk of
  developing secondary neoplasms, even with unrelated donor transplants.
raw_completion_output: |-
  primary_disease: Fanconi anemia
  medical_actions: Bone marrow transplant; Fludarabine-based reduced intensity conditioning regimen; In vivo T cell depletion; HSCT; Matched unrelated donor transplant; Mismatched and unrelated donor transplants; Ex vivo T-cell depletion; GVHD prophylaxis; MSD transplant; UCB and BM grafts
  symptoms: Inherited BMF syndromes; DNA instability; Immediate and late complications of HSCT; Risk of secondary malignancies; Acute or chronic GVHD; Viral reactivations; Full immune reconstitution; Stable chimerism
  chemicals: Fludarabine; Alemtuzumab; Busulfan; Cyclophosphamide; Ciclosporin; Mycophenolate; TBI
  action_annotation_relationships: Bone marrow transplant (with fludarabine, alemtuzumab, busulfan, cyclophosphamide) TREATS inherited BMF syndromes IN Fanconi anemia; HSCT TREATS inherited BMF syndromes IN Fanconi anemia; Fludarabine-based reduced intensity conditioning regimen PREVENTS immediate and late complications of HSCT IN Fanconi anemia; Fludarabine-based reduced intensity conditioning regimen PREVENTS risk of secondary malignancies IN Fanconi anemia; In vivo T cell depletion PREVENTS acute or chronic GVHD IN Fanconi anemia; GVHD prophylaxis (with ciclosporin and mycophenolate) PREVENTS acute or chronic GVHD IN Fanconi anemia; MSD transplant USING UCB and BM grafts TREATS inherited BMF syndromes IN Fanconi anemia; Alemtuzumab IN conditioning PREVENTS development of GVHD IN Fanconi anemia; Alemtuzumab IN conditioning REDUCES risk of developing secondary neoplasms IN Fanconi anemia
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Alemtuzumab IN conditioning REDUCES risk of developing secondary neoplasms IN Fanconi anemia

  ===

extracted_object:
  primary_disease: MONDO:0019391
  medical_actions:
    - Bone marrow transplant
    - Fludarabine-based reduced intensity conditioning regimen
    - In vivo T cell depletion
    - MAXO:0000747
    - Matched unrelated donor transplant
    - Mismatched and unrelated donor transplants
    - Ex vivo T-cell depletion
    - GVHD prophylaxis
    - MSD transplant
    - UCB and BM grafts
  symptoms:
    - Inherited BMF syndromes
    - DNA instability
    - Immediate and late complications of HSCT
    - Risk of secondary malignancies
    - Acute or chronic GVHD
    - Viral reactivations
    - Full immune reconstitution
    - Stable chimerism
  chemicals:
    - Fludarabine
    - Alemtuzumab
    - CHEBI:28901
    - CHEBI:4027
    - CHEBI:4031
    - CHEBI:62932
    - TBI
  action_annotation_relationships:
    - subject: Bone marrow transplant
      predicate: TREATS
      object: inherited BMF syndromes
      qualifier: MONDO:0019391
      subject_qualifier: with fludarabine, alemtuzumab, busulfan, cyclophosphamide
      subject_extension: fludarabine, alemtuzumab, busulfan, cyclophosphamide
    - subject: MAXO:0000747
      predicate: TREATS
      object: inherited BMF syndromes
      qualifier: MONDO:0019391
    - subject: reduced intensity conditioning regimen
      predicate: PREVENTS
      object: complications of HSCT
      qualifier: MONDO:0019391
      subject_qualifier: Fludarabine-based
      object_qualifier: immediate and late
      subject_extension: Fludarabine
      object_extension: immediate and late
    - subject: reduced intensity conditioning regimen
      predicate: PREVENTS
      object: risk of secondary malignancies
      qualifier: MONDO:0019391
      subject_qualifier: Fludarabine-based
      subject_extension: Fludarabine
    - subject: T cell depletion
      predicate: PREVENTS
      object: acute or chronic GVHD
      qualifier: MONDO:0019391
      subject_qualifier: in vivo
      subject_extension: T cell depletion
    - subject: GVHD prophylaxis
      predicate: PREVENTS
      object: acute or chronic GVHD
      qualifier: MONDO:0019391
      subject_qualifier: with ciclosporin and mycophenolate
      subject_extension: ciclosporin and mycophenolate
    - subject: MSD transplant
      predicate: TREATS
      object: BMF syndromes
      qualifier: MONDO:0019391
      object_qualifier: inherited
      subject_extension: UCB and BM grafts
      object_extension: inherited BMF syndromes
    - subject: conditioning
      predicate: PREVENTS
      object: development of GVHD
      qualifier: MONDO:0019391
      subject_extension: Alemtuzumab
    - subject: conditioning
      predicate: REDUCES
      object: risk of developing secondary neoplasms
      qualifier: MONDO:0019391
      subject_qualifier: Alemtuzumab
      subject_extension: Alemtuzumab
      object_extension: secondary neoplasms
named_entities:
  - id: MONDO:0019391
    label: Fanconi anemia
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation (HSCT)
  - id: CHEBI:18198
    label: ADCs
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000750
    label: conditioning regimens
  - id: CHEBI:37153
    label: Calcineurin inhibitor
  - id: CHEBI:38215
    label: Calcium channel blocker
  - id: CHEBI:4031
    label: Cyclosporine
  - id: CHEBI:8069
    label: Phenobarbital
  - id: CHEBI:2668
    label: Amlodipine
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MAXO:0000016
    label: Cellular therapy
  - id: HP:0001871
    label: Blood dyscrasias
  - id: MAXO:0000595
    label: Radiography
  - id: HP:0005528
    label: Bone marrow failure
  - id: HP:0034057
    label: Congenital defects
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:44185
    label: Methotrexate
  - id: MONDO:0005233
    label: Non-small cell lung cancer (NSCLC)
  - id: CHEBI:33364
    label: Platinum
  - id: MAXO:0000647
    label: chemotherapy
  - id: HP:0030358
    label: Non-small cell lung cancer
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: HP:0002863
    label: Myelodysplasia
  - id: HP:0001909
    label: Leukemia
  - id: MONDO:0016624
    label: Hereditary anemia
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0005570
    label: Hematological disorders
  - id: HP:0002664
    label: cancer
  - id: MONDO:0015253
    label: Diamond Blackfan anemia
  - id: MAXO:0000600
    label: Kidney replacement therapy (KRT)
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003259
    label: Elevated serum creatinine (SCr > 100micromol/l)
  - id: MONDO:0001529
    label: Bone marrow failure (BMF)
  - id: HP:0002860
    label: oral squamous cell carcinoma (SCC)
  - id: MONDO:0100339
    label: Fanconi anemia (FA)
  - id: CHEBI:28680
    label: Ara-C
  - id: CHEBI:27899
    label: Cisplatin
  - id: HP:0011793
    label: Malignant tumors
  - id: HP:0000818
    label: Endocrinopathies
  - id: HP:0002745
    label: Oral leukoplakia
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:61049
    label: Tacrolimus
  - id: HP:0002910
    label: elevated liver function tests
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:231614
    label: Nivolumab
  - id: CHEBI:25016
    label: PBS
  - id: MONDO:0009693
    label: Multiple Myeloma
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:229764
    label: Selinexor
  - id: CHEBI:229762
    label: Eltanexor
  - id: HP:0006775
    label: Multiple Myeloma
  - id: CHEBI:229763
    label: exportin 1 inhibitors
  - id: MONDO:0015909
    label: aplastic anemia
  - id: HP:0004808
    label: Acute myeloid leukaemia
  - id: MAXO:0000004
    label: Surgery
  - id: MAXO:0000014
    label: Radiotherapy
  - id: MONDO:0001881
    label: Septic shock
  - id: MAXO:0001021
    label: Antimicrobial treatment
  - id: MAXO:0000174
    label: Antifungal treatment
  - id: HP:0001876
    label: Pancytopenia
  - id: HP:0001945
    label: Fever
  - id: CHEBI:133748
    label: Citrate
  - id: CHEBI:41879
    label: Dexamethasone
  - id: CHEBI:33281
    label: Antimicrobial
  - id: CHEBI:35718
    label: Antifungal
  - id: MONDO:0044033
    label: Posterior reversible encephalopathy syndrome (PRES)
  - id: MAXO:0010030
    label: Bone marrow transplantation
  - id: MAXO:0001188
    label: Laparoscopy
  - id: HP:0000988
    label: Skin rash
  - id: MONDO:0010161
    label: Tyrosinemia Type 1
  - id: HP:0001919
    label: acute kidney injury (AKI)
  - id: HP:0000822
    label: hypertension
  - id: MAXO:0001298
    label: therapy
  - id: HP:0040012
    label: Increased chromosomal breakage
  - id: MONDO:0004631
    label: Tongue cancer (TC)
  - id: CHEBI:4735
    label: EDTA
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0025085
    label: Blood in stool
  - id: HP:0000568
    label: Microphthalmia
  - id: HP:0000482
    label: microcornea
  - id: HP:0000508
    label: ptosis
  - id: HP:0011496
    label: limbal neovascularization
  - id: HP:0001097
    label: keratoconjunctivitis sicca
  - id: CHEBI:62932
    label: Mycophenolate
